4514-28-7

Basic information

• Product Name: 4-(benzyloxy)-1-broMo-2-nitrobenzene
• Synonyms: 4-(benzyloxy)-1-broMo-2-nitrobenzene
• CAS NO: 4514-28-7
• Molecular Formula: C13H10BrNO3
• Molecular Weight: 308.131
• Mol File: 4514-28-7.mol
• Article Data: 7

Chemical Properties

• CAS DataBase Reference: 4-(benzyloxy)-1-broMo-2-nitrobenzene(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(benzyloxy)-1-broMo-2-nitrobenzene(4514-28-7)
• EPA Substance Registry System: 4-(benzyloxy)-1-broMo-2-nitrobenzene(4514-28-7)

Safety Data

• Hazardous Substances Data: 4514-28-7(Hazardous Substances Data)

Upstream product

• 5344-78-5 4-bromo-3-nitroanizole 
• 78137-76-5 4-bromo-3-nitrophenol 
• 100-39-0 benzyl bromide 

Downstream Products

• 4514-29-8 N-Methyl-2-nitro-4-benzyloxy-diphenylamin-2'-carbonsaeure 
• 1313530-04-9 C₁₈H₁₇NO₃ 
• 1313530-07-2 C₁₉H₁₆N₂O₃ 
• 290333-11-8 4-benzyloxy-7-bromoindole 
• 119879-90-2 5-(Benzyloxy)-2-bromophenylamine 

Relevant articles and documents

BENZOCYCLOBUTANE DERIVATIVES USEFUL AS DUAL SGLT1/SGLT2 MODULATORS

The present invention is directed to benzocyclobutane derivatives, pharmaceutical compositions containing them and their use in the treatment of disorders and conditions modulated by SGLT activity, more particularly dual SGLT1/2 activity. More particularly, the compounds of the present invention are useful in the treatment of for example, Type II diabetes mellitus, Syndrome X, and complications and symptoms associated with said disorders.

Indazoles, benzothiazoles, benzoisothiazoles, benzisoxazoles, pyrazolopyridines, isothiazolopyridines, and preparation and uses thereof

The present invention relates generally to the field of ligands for nicotinic acetylcholine receptors (nACh receptors), activation of nACh receptors, and the treatment of disease conditions associated with defective or malfunctioning nicotinic acetylcholine receptors, especially of the brain. Further, this invention relates to novel compounds (e.g., indazoles and benzothiazoles), which act as ligands for the α7 nACh receptor subtype, methods of preparing such compounds, compositions containing such compounds, and methods of use thereof.

2,3-Dimethoxybenzo[i]phenanthridines: Topoisomerase I-targeting anticancer agents

Appropriately substituted benzo[i]phenanthridines structurally related to nitidine, a benzo[c]phenanthridine alkaloid with antitumor activity, are active as topoisomerase I-targeting agents. Studies on benzo[i]phenanthridines have indicated analogues that possess a 2,3-methylenedioxy moiety and at least one and preferably two methoxyl groups at the 8- and 9-positions, such as 8,9-dimethoxy-2,3-methylenedioxybenzo[i]phenanthridine, 2, are active as topoisomerase I-targeting agents. Tetramethoxylated benzo[i]phenanthridines, wherein the 2,3-methylenedioxy moiety is replaced with methoxyl groups at the 2- and 3-position, are inactive as a topoisomerase I-targeting agent. These results initially suggested that the 2,3-methylenedioxy moiety was critical to the retention of potent activity. Further studies revealed that 2,3-dimethoxy-8,9-methylenedioxybenzo[i]phenanthridine, 7a, is more potent than 2 as a topoisomerase I-targeting agent. The observation that 2,3-dimethoxylated benzo[i]phenanthridines can actually exhibit enhanced activity prompted the present study in which several 8-substituted 2,3-dimethoxybenzo[i]phenanthridines were prepared and their pharmacological activities evaluated. The influence of NH2, CN, CH2OH, OBn, OCH3, OH, and NHCOCH3substituents at the 8-position on the relative activity of these 2,3-dimethoxybenzo[i]phenanthridines was examined. Relative to these derivatives, 7a was the most potent topoisomerase I-targeting agent, possessing similar cytotoxicity to that of nitidine in the human lymphoblast tumor cell line, RPMI8402.